Compare TOMZ & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | LPCN |
|---|---|---|
| Founded | 1979 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 13.8M |
| IPO Year | N/A | N/A |
| Metric | TOMZ | LPCN |
|---|---|---|
| Price | $0.75 | $4.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $7.00 |
| AVG Volume (30 Days) | 13.8K | ★ 35.7K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,688,341.00 | $4,322,693.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $68.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $2.52 |
| 52 Week High | $1.50 | $5.50 |
| Indicator | TOMZ | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 79.21 |
| Support Level | $0.73 | $3.05 |
| Resistance Level | $0.80 | $3.39 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 12.95 | 90.64 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.